Abstract
Chronic hepatitis B affects approximately 350 million individuals worldwide leading to approximately 500,000 deaths annually. Current therapy includes immune modulators such as IFN-α and the oral antiviral agents, nucleoside analogs such as lamivudine and entecavir, and nucleotide analogs such as adefovir and tenofovir. Recently, telbivudine was approved in the USA for treatment of HBV disease. It is a synthetic nucleoside analog of thymidine that requires phosphorylation to convert to the active triphosphate form. Telbivudine is rapidly absorbed with a long half-life allowing for once-daily dosing. Clinical trials have demonstrated superior antiviral efficacy compared with lamivudine. Telbivudine has shown good correlations between antiviral efficacy at 24 weeks and a favorable outcome at 2 years. Telbivudine is well-tolerated, although monitoring for myopathies is recommended. Telbivudine resistance rates were lower compared with lamivudine. Telbivudine is an option for monotherapy in naive patients or for use in combination therapy in the treatment of chronic hepatitis B.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
